@article{0b25f6463e5c473384be75d076ac2521,
title = "The antimicrobial agent C31G is effective for therapy for HSV-1 ocular keratitis in the rabbit eye model",
abstract = "The amphoteric C31G solution contains equimolar alkyl dimethlyglycine and alkyl dimethyl amine oxide buffered with citric acid. C31G acts as a broad spectrum antiviral and an antibacterial. No previous in vivo studies have been done to test C31G in an animal model of HSV-1 ocular keratitis. We assessed the anti-herpetic activity of C31G in the rabbit eye model using three treatment groups: (1) 1% trifluorothymidine (TFT); (2) 0.25% C31G plus 0.5% hydroxypropyl methylcellulose (HPMC); and (3) vehicle, 0.5% HPMC. Scarified rabbit corneas were inoculated with the HSV-1 strain McKrae. On post inoculation (PI) day 3, rabbits were placed in three balanced groups based on slit-lamp examination (SLE) scores. Treatment began on PI day 3, five times a day for five consecutive days. In addition to the daily, masked SLE scoring, the eyes were assessed daily for stromal opacity, scleral inflammation, neovascularization, eyelid inflammation, inflammatory discharge, and epiphora. C31G and TFT were very effective in reducing the lesions and pathogenesis associated with HSV-1 ocular keratitis. The vehicle control scores were significantly higher and did not effectively treat HSV-1 keratitis. C31G has the potential to be used to treat herpetic keratitis as well as other herpetic topical lesions in humans.",
keywords = "Anti-herpetic, C31G, HSV-1 keratitis, Novel anti-herpetic, Novel anti-viral, Rabbit",
author = "Hill, {James M.} and Stern, {Ethan M.} and Bhattacharjee, {Partha S.} and Daniel Malamud and Christian Clement and Paulo Rodriguez and Lukiw, {Walter J.} and Ochoa, {Augusto C.} and Foster, {Timothy P.} and Cruz Velasco and McFerrin, {Harris E.}",
note = "Funding Information: This research was supported in part by funding from the National Eye Institute grants EY014289 (Richard Bax), R21-EY019144 647 (PSB), R01-EY006311 (JMH); National Cancer Institute R01-CA107974 (ACO), R21-CA162133 (PCR); the NIH National Institute on Aging AG18031 (WJL) and AG038834 (WJL), AG23085 (JMH); P20GMM103501 (ACO, TPF, PCR); National Center for Research Resources (P20RR016456), the National Institute of General Medical Sciences (P20GM103424), Louisiana Cancer Research Consortium and the NIH-RCM1 grant #5G12RR02620 from the National Institute on Minority Health and Health Disparities (HEM). This research was also supported by an unrestricted research grant from the LSU Health Sciences Center (JMH); Transitional Research Initiative grants (WJL and JMH); a research grant from LSUHSC (JMH); a Research to Prevent Blindness (RPB) Senior Scientific Investigator Award (JMH); an unrestricted grant to the LSU Eye Center from RPB, New York, NY; the Louisiana Biotechnology Research Network (WJL, JMH); an Alzheimer Association Investigator-Initiated Research Grant IIRG-09-131729 (WJL); the Louisiana Cancer Research Consortium (PSB); the Louisiana Lions Eye Foundation, New Orleans; the Louisiana Vaccine Center sponsored by the Louisiana Board of Regents (JMH).",
year = "2013",
doi = "10.1016/j.antiviral.2013.07.002",
language = "English (US)",
volume = "100",
pages = "14--19",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier B.V.",
number = "1",
}